President-elect Donald Trump has announced his intention to nominate Robert F. Kennedy Jr. to lead the Department of Health and Human Services (HHS), a move that has sparked significant debate across the political and medical sectors. Kennedy, a former independent presidential candidate and environmental lawyer, has frequently criticized federal health agencies and the pharmaceutical industry, pledging to focus on what he describes as a 'chronic disease epidemic.' Supporters of the move suggest Kennedy will bring much-needed reform and transparency to government health oversight. However, several public health officials and medical experts have raised concerns, citing Kennedy's history of skepticism toward vaccine safety and established scientific consensus. The announcement had an immediate impact on the financial sector, with shares of major vaccine manufacturers experiencing a decline in late-day trading. If confirmed by the Senate, Kennedy would oversee the FDA, CDC, and NIH, as well as the administration of Medicare and Medicaid.